Biogen New Ventures | Activity | F4

Team Portfolio Raise Essays

F4/Biogen New Ventures/Activity

Biogen New Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Participated in Estuary's $93M Series A, led by RA Capital, for kidney disease gene therapies.

Estuary Biotherapeutics

Estuary Biotherapeutics Biogen New Ventures

fiercebiotech.comOCT 15, 2026

OCT 15, 2026

Investment

Participated in Altay's $37M Series A for an oral DUX4 inhibitor for FSHD; Chelsea Johnson joined the board.

Altay Therapeutics

Altay Therapeutics Biogen New Ventures

biospace.comOCT 14, 2026

OCT 14, 2026

Press

Johnson described New Ventures as equity investing that leads into future partnerships with Biogen.

Fierce Biotech interview on Biogen's VC mindset and New Ventures

Biogen New Ventures

fiercebiotech.comJUN 16, 2026

JUN 16, 2026

New Fund

Biogen formally launched New Ventures, a corporate venture arm led by Chelsea Johnson, to invest in external life sciences startups.

Biogen New Ventures launch

Biogen New Ventures

globalventuring.comNOV 6, 2025

NOV 6, 2025

Team Change

Hired Chelsea Johnson from Atlas Venture to lead New Ventures.

Chelsea Johnson joined as Head of New Ventures

Biogen New Ventures

globalventuring.comNOV 2025

NOV 2025